AstraZeneca said on Tuesday it plans to invest $50 billion in the United States by 2030, funding a new multibillion-dollar manufacturing facility in Virginia and expanding research, development, and cell therapy operations in Maryland, Massachusetts, California, Indiana, and Texas.
The Virginia site will manufacture drug substances for weight management and metabolic treatments, including oral GLP-1 drugs, baxdrostat, oral PCSK9 inhibitors, and combination therapies. The plant will produce small molecules, peptides, and oligonucleotides, AstraZeneca said.
AstraZeneca expects the move to help drive annual revenue to $80 billion by 2030, with half of that generated in the United States, its largest market, accounting for 42 percent of total sales….